share_log

Cantor Fitzgerald Initiates Coverage On KemPharm With Overweight Rating, Announces Price Target of $20

Cantor Fitzgerald Initiates Coverage On KemPharm With Overweight Rating, Announces Price Target of $20

康託·菲茨傑拉德以增持評級啟動對KemPharm的報道,宣佈目標價為20美元
Benzinga Real-time News ·  2022/11/17 06:22

Cantor Fitzgerald analyst Louis Chen initiates coverage on KemPharm (NASDAQ:KMPH) with a Overweight rating and announces Price Target of $20.

Cantor Fitzgerald分析師Louis Chen在納斯達克(KemPharm)上以增持評級啟動報道,並宣佈目標價為20美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論